Literature DB >> 10597254

Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.

L Ma1, C Gauvillé, Y Berthois, G Millot, G R Johnson, F Calvo.   

Abstract

The epidermal growth factor (EFG) family of receptors and their respective ligands play a major role in breast cancer progression and are the targets of new therapeutic approaches. Following immortalization with SV40 T antigen of normal human breast epithelial cells, a transformed variant cell line (NS2T2A1) was selected for its increased tumorigenicity in nude mice. This cell line was shown to have a higher expression of EGF receptors (EGFR) and amphiregulin (AR) when compared to their normal counterparts or less aggressive transformed cells. Dual staining of EGFR and AR was observed in 50-60% of NS2T2A1 cells, while 30-40% cells expressed AR only. To explore the potential tumorigenic role of AR, a 1.1 kb AR cDNA in an antisense orientation was transfected in NS2T2A1 cells. Three clones, selected by hygromycin B, expressed AR antisense RNA (AR AS1, AR AS2 and AR AS3 cell lines) in which AR protein expression was reduced (ranging from about 50 to < 5%). The anchorage-independent growth of AR AS cell lines was reduced to levels ranging from 32.4-6.8% relative to the control cell line transfected with the vector alone. The clones expressing AR antisense RNA showed a reversion of the malignant phenotype when injected in nude mice, since a significant reduction of tumor intake was observed coincident with a significant tumor mass reduction (> 96%). Moreover, intra-tumoral vascularization decreased significantly in tumors derived from AR AS cells (26.7, 70.7 and 50.4% of control). These in vitro and in vivo data reveal the oncogenic nature of AR in transformed breast epithelial cells and imply a role for AR in tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597254     DOI: 10.1038/sj.onc.1203042

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.

Authors:  Sangjun Lee; Dan Medina; Anna Tsimelzon; Syed K Mohsin; Sufeng Mao; Yun Wu; D Craig Allred
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

2.  Amphiregulin as a Novel Serum Marker of Puberty in Girls.

Authors:  Frank M Biro; Susan M Pinney; Richard C Schwartz; Bin Huang; Ashley M Cattran; Sandra Z Haslam
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-02-16       Impact factor: 1.814

3.  Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.

Authors:  Lindsey K Bade; Jodi E Goldberg; Hazel A Dehut; Majken K Hall; Kathryn L Schwertfeger
Journal:  J Cell Sci       Date:  2011-08-24       Impact factor: 5.285

4.  The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation.

Authors:  Aiwen Dong; Aparna Gupta; Reetesh K Pai; May Tun; Anson W Lowe
Journal:  J Biol Chem       Date:  2011-03-26       Impact factor: 5.157

5.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  Cyclin D1 determines estrogen signaling in the mammary gland in vivo.

Authors:  Mathew C Casimiro; Chenguang Wang; Zhiping Li; Gabriele Di Sante; Nicole E Willmart; Sankar Addya; Lei Chen; Yang Liu; Michael P Lisanti; Richard G Pestell
Journal:  Mol Endocrinol       Date:  2013-07-17

Review 7.  The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.

Authors:  Mark D Sternlicht; Susan W Sunnarborg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-10       Impact factor: 2.673

Review 8.  Amphiregulin as a novel target for breast cancer therapy.

Authors:  Nicole E Willmarth; Stephen P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

9.  Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice.

Authors:  David H Nguyen; Haoxu Ouyang; Jian-Hua Mao; Lynn Hlatky; Mary Helen Barcellos-Hoff
Journal:  Cancer Res       Date:  2014-10-03       Impact factor: 12.701

Review 10.  Amphiregulin: role in mammary gland development and breast cancer.

Authors:  Jean McBryan; Jillian Howlin; Silvia Napoletano; Finian Martin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-09       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.